William Westlin

5.4k total citations · 1 hit paper
65 papers, 3.0k citations indexed

About

William Westlin is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, William Westlin has authored 65 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 19 papers in Oncology and 10 papers in Genetics. Recurrent topics in William Westlin's work include Peptidase Inhibition and Analysis (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Neuropeptides and Animal Physiology (7 papers). William Westlin is often cited by papers focused on Peptidase Inhibition and Analysis (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Neuropeptides and Animal Physiology (7 papers). William Westlin collaborates with scholars based in United States, Japan and Austria. William Westlin's co-authors include Michael A. Gimbrone, Kevin Mullane, Rosana Kapeller, Geraldine Harriman, H. James Harwood, Rosemary Kraemer, Jeremy R. Greenwood, Sathesh Bhat, Matthew Labenski and Gerhard Hannig and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Investigation.

In The Last Decade

William Westlin

64 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models

2016 390 citations Geraldine Harriman, William Westlin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Westlin United States	24	1.2k	555	545	492	404	65	3.0k
Xianxian Zheng United States	20	1.7k 1.3×	524 0.9×	1.1k 2.1×	238 0.5×	265 0.7×	30	3.4k
Antonella Naldini Italy	32	964 0.8×	493 0.9×	389 0.7×	584 1.2×	132 0.3×	97	2.7k
Stephen Gately United States	24	2.0k 1.6×	1.2k 2.1×	675 1.2×	178 0.4×	158 0.4×	40	3.5k
Olivier Dormond Switzerland	33	1.7k 1.4×	584 1.1×	1.1k 2.1×	422 0.9×	213 0.5×	72	3.3k
Lakshmi Puttagunta Canada	23	1.5k 1.2×	812 1.5×	291 0.5×	456 0.9×	110 0.3×	62	3.3k
Carlo M. Croce United States	22	2.4k 1.9×	389 0.7×	607 1.1×	604 1.2×	317 0.8×	31	3.6k
Martin Highley United Kingdom	21	1.2k 1.0×	518 0.9×	921 1.7×	221 0.4×	267 0.7×	62	3.1k
Oliver Stoeltzing United States	43	3.0k 2.4×	1.4k 2.5×	1.6k 2.8×	383 0.8×	312 0.8×	73	4.6k
Toru Kumagai Japan	32	1.1k 0.9×	741 1.3×	1.4k 2.6×	288 0.6×	245 0.6×	156	3.1k
James F. Callahan United States	22	2.7k 2.2×	359 0.6×	691 1.3×	325 0.7×	152 0.4×	54	4.0k

Countries citing papers authored by William Westlin

Since Specialization

Citations

This map shows the geographic impact of William Westlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Westlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Westlin more than expected).

Fields of papers citing papers by William Westlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Westlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Westlin. The network helps show where William Westlin may publish in the future.

Co-authorship network of co-authors of William Westlin

This figure shows the co-authorship network connecting the top 25 collaborators of William Westlin. A scholar is included among the top collaborators of William Westlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Westlin. William Westlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gracey, Eric, Melissa Lim, Zoya Qaiyum, et al.. (2020). TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. Journal of Clinical Investigation. 130(4). 1863–1878. 54 indexed citations

Westlin, William, Geraldine Harriman, H. James Harwood, et al.. (2016). NDI-010976, a Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: Pharmacodynamic Effects on Hepatic De Novo Lipogenesis in Obese but Otherwise Healthy Adult Male Volunteers. Journal of Hepatology. 64(2). S190–S191. 4 indexed citations

Kelly, Priscilla N., Donna L. Romero, Yibin Yang, et al.. (2015). Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. The Journal of Experimental Medicine. 212(13). 2189–2201. 128 indexed citations

Eda, Homare, Loredana Santo, Diana Cirstea, et al.. (2014). A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 28(9). 1892–1901. 37 indexed citations

Arico-Muendel, Christopher C., Bruce Belanger, Dennis R. Benjamin, et al.. (2013). Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity. Drug Metabolism and Disposition. 41(4). 814–826. 9 indexed citations

Evans, Erica N, Richland Tester, Russell Karp, et al.. (2013). Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans. Journal of Pharmacology and Experimental Therapeutics. 346(2). 219–228. 171 indexed citations

Evindar, Ghotas, et al.. (2012). Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1. Bioorganic & Medicinal Chemistry Letters. 23(2). 472–475. 2 indexed citations

Westlin, William, Heather Lounsbury, Bruce A. Silver, et al.. (2012). Abstract 1745: Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial. Cancer Research. 72(8_Supplement). 1745–1745. 4 indexed citations

Brown, Jennifer R., Jeff P. Sharman, Wael A. Harb, et al.. (2012). Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).. Journal of Clinical Oncology. 30(15_suppl). 8032–8032. 29 indexed citations

10.

Walter, Annette O., Henry J. Haringsma, Kevin Lin, et al.. (2011). Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.. Molecular Cancer Therapeutics. 10(11_Supplement). C189–C189. 11 indexed citations

11.

Evans, Erica N, Richland Tester, Prasoon Chaturvedi, et al.. (2011). Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,. Blood. 118(21). 3485–3485. 19 indexed citations

12.

Hagel, Margit, Deqiang Niu, Thia St Martin, et al.. (2010). Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine. Nature Chemical Biology. 7(1). 22–24. 77 indexed citations

13.

Hannig, Gerhard, et al.. (2007). Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI‐2458. Arthritis & Rheumatism. 56(3). 850–860. 20 indexed citations

14.

Bernier, Sylvie G., Douglas Lazarus, Matthew Labenski, et al.. (2004). A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proceedings of the National Academy of Sciences. 101(29). 10768–10773. 84 indexed citations

15.

Perruzzi, Carole, Mary C. Whelan, Donald R. Senger, et al.. (2003). Functional Overlap and Cooperativity Among αv and β1 Integrin Subfamilies During Skin Angiogenesis. Journal of Investigative Dermatology. 120(6). 1100–1109. 34 indexed citations

16.

Anderson, Stasia A., Randall K. Rader, William Westlin, et al.. (2000). Magnetic resonance contrast enhancement of neovasculature with ?v?3-targeted nanoparticles. Magnetic Resonance in Medicine. 44(3). 433–439. 209 indexed citations

17.

Westlin, William & Kevin Mullane. (1989). Alleviation of myocardial stunning by leukocyte and platelet depletion.. Circulation. 80(6). 1828–1836. 68 indexed citations

18.

Mullane, Kevin, William Westlin, & Rosemary Kraemer. (1988). Activated Neutrophils Release Mediators That May Contribute to Myocardial Injury and Dysfunction Associated with Ischemia and Reperfusiona. Annals of the New York Academy of Sciences. 524(1). 103–121. 100 indexed citations

19.

Powers, C. Andrew & William Westlin. (1987). Glandular Kallikrein Levels in the Rat Anterior Pituitary during the Estrous Cycle and Pregnancy1. Biology of Reproduction. 37(2). 306–310. 7 indexed citations

20.

Westlin, William, et al.. (1958). THE TREATMENT OF ALLERGY WITH EXTRACT OF TOXICODENDRON QUERCIFOLIA: A CONTROLLED SERIES. PEDIATRICS. 22(5). 887–891. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact